Trimtech Therapeutics develops small molecule degraders that selectively eliminate disease-causing protein aggregates. Their TRIMTACs® and TRIMGLUEs® leverage the TRIM21 E3 ligase to target and degrade pathological assemblies, preserving functional monomeric proteins for treating neurodegenerative and inflammatory disorders.
Funding
Funding not disclosed
Founders
Product
Problem
Protein aggregates and assemblies are implicated in numerous severe neurodegenerative and inflammatory disorders. However, the non-aggregated, functional forms of these same proteins are often critical for healthy cellular function, presenting a challenge for therapeutic intervention.
Solution
Trimtech Therapeutics is developing a pipeline of proprietary small molecule degraders, TRIMTACs® and TRIMGLUEs®, designed to selectively target and eliminate disease-causing protein aggregates. This approach leverages the unique mechanism of the TRIM21 E3 ligase, which is activated by substrate-induced clustering of multimeric targets like aggregates. By directing TRIM21 to these pathological assemblies, Trimtech's therapeutics can induce their degradation via the ubiquitin-proteasome system while preserving the functional monomeric forms of the proteins. This targeted degradation strategy aims to address significant unmet needs in indications such as Alzheimer's disease, Huntington's disease, and other inflammatory conditions.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing novel therapeutics for neurodegenerative and inflammatory diseases.
Features
- Proprietary TRIMTACs®: Bispecific small molecules designed to recruit the TRIM21 E3 ligase to specific target proteins, facilitating their degradation.
- Proprietary TRIMGLUEs®: Small molecules that induce degradation by exploiting cryptic mutual binding interactions between a target and TRIM21, applicable even when specific ligands are unknown.
- Aggregate Selectivity: The technology inherently targets multimeric forms (oligomers, aggregates) of proteins due to TRIM21's substrate-induced clustering activation mechanism, preserving monomeric protein function.
- TRIM21 E3 Ligase Platform: Leverages the innate catalytic mechanism of TRIM21, a widely expressed E3 ligase, for targeted protein degradation.
- Small Molecule Modalities: Development of orally active small molecule degraders, offering potential for broad patient access and administration convenience.
- Therapeutic Focus: Programs targeting protein aggregates implicated in neurodegenerative diseases (e.g., Alzheimer's, Huntington's) and inflammatory disorders.